Will competition from Authorized Generics further drive down the price for off-patent pharmaceuticals, giving consumers alternatives to purchasing their drugs from foreign suppliers?
Related Questions
- Doesn’t the marketing of Authorized Generics offer consumers benefits during the 180-day exclusivity period while preserving the value of patent challenges?
- What benefits do consumers recieve as a result of competition in private sector markets?
- How can employers and consumers leverage competition to lower cost and improve quality?
